- Zanubrutinib, sold
under the
brand name
Brukinsa, is an
anticancer medication used for the
treatment of
mantle cell
lymphoma (MCL), Waldenström's macroglobulinemia...
- in
patients who have been
treated with an anti-CD20 regimen. In 2023,
Brukinsa, the Bruton's
tyrosine kinase inhibitor crossed blockbuster threshold to...
-
lymphocytic leukemia (CLL) and
Small lymphocytic lymphoma (SLL)
Zanubrutinib (
Brukinsa) for
mantle cell lymphoma,
chronic lymphocytic leukemia (CLL), or small...
-
short and
patients typically relapse. In
November 2019,
zanubrutinib (
Brukinsa) was
approved in the
United States with an
indication for the treatment...
- Lunesta, Latisse, Entresto, Tremfya, Brineura, Privigen, Zykadia, Tecfidera,
Brukinsa, Zolgensma, Xpovio, and Qwo.
Brand Institute notably created and validated...
